- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-EGF/ HOMG4/ URG monoclonal antibody
Anti-EGF/ HOMG4/ URG antibody for FACS & in-vivo assay
Go to EGF/EGF products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-T33425-Ab-1/ GM-Tg-hg-T33425-Ab-2 | Anti-Human EGF monoclonal antibody | Human |
| GM-Tg-rg-T33425-Ab-1/ GM-Tg-rg-T33425-Ab-2 | Anti-Rat EGF monoclonal antibody | Rat |
| GM-Tg-mg-T33425-Ab-1/ GM-Tg-mg-T33425-Ab-2 | Anti-Mouse EGF monoclonal antibody | Mouse |
| GM-Tg-cynog-T33425-Ab-1/ GM-Tg-cynog-T33425-Ab-2 | Anti-Cynomolgus/ Rhesus macaque EGF monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-T33425-Ab-1/ GM-Tg-felg-T33425-Ab-2 | Anti-Feline EGF monoclonal antibody | Feline |
| GM-Tg-cang-T33425-Ab-1/ GM-Tg-cang-T33425-Ab-2 | Anti-Canine EGF monoclonal antibody | Canine |
| GM-Tg-bovg-T33425-Ab-1/ GM-Tg-bovg-T33425-Ab-2 | Anti-Bovine EGF monoclonal antibody | Bovine |
| GM-Tg-equg-T33425-Ab-1/ GM-Tg-equg-T33425-Ab-2 | Anti-Equine EGF monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-T33425-Ab-1/ GM-Tg-hg-T33425-Ab-2; GM-Tg-rg-T33425-Ab-1/ GM-Tg-rg-T33425-Ab-2; GM-Tg-mg-T33425-Ab-1/ GM-Tg-mg-T33425-Ab-2; GM-Tg-cynog-T33425-Ab-1/ GM-Tg-cynog-T33425-Ab-2; GM-Tg-felg-T33425-Ab-1/ GM-Tg-felg-T33425-Ab-2; GM-Tg-cang-T33425-Ab-1/ GM-Tg-cang-T33425-Ab-2; GM-Tg-bovg-T33425-Ab-1/ GM-Tg-bovg-T33425-Ab-2; GM-Tg-equg-T33425-Ab-1/ GM-Tg-equg-T33425-Ab-2 |
| Products Name | Anti-EGF monoclonal antibody |
| Format | mab |
| Target Name | EGF |
| Protein Sub-location | Transmembrane Protein |
| Category of antibody | FACS/Biofunctional Antibody, Therapeutics Target antibody, Diagnostic target antibody, Cytokine antibody |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD). |
| Tag | Fc |
| Products description | Pre-made anti-EGF benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | Products Developing | Multi-species EGF/ HOMG4/ URG VLP (virus-like particle) (Products Developing) |
| Cytokine | GM-Tg-g-T33425-Ag-1 | epidermal growth factor (EGF) protein |
| ORF Viral Vector | vGMAD000135 | human EGF Adenovirus particle |
| ORF Viral Vector | pGMAD000135 | human EGF Adenovirus plasmid |
| ORF Viral Vector | pGMAD000607 | house mouse Egf Adenovirus plasmid |
| ORF Viral Vector | vGMAD000607 | house mouse Egf Adenovirus particle |
Target information
| Target ID | GM-T33425 |
| Target Name | EGF |
| Gene ID | 1950,13645,25313,698619,403657,493978,530315,106782874 |
| Gene Symbol and Synonyms | CEGF,EGF,HOMG4,URG |
| Uniprot Accession | P01133,P07522,Q9BEA0,Q95ND4 |
| Uniprot Entry Name | EGF_HUMAN,EGF_RAT,EGF_FELCA,EGF_CANLF |
| Protein Sub-location | Transmembrane Protein |
| Category | Therapeutics Target, Diagnostics Biomarker, Immuno-oncology Target, Cytokine Target |
| Disease | Nephrotoxicity |
| Gene Ensembl | ENSG00000138798 |
| Target Classification | Checkpoint-Immuno Oncology |
The target: EGF, gene name: EGF, also named as HOMG4, URG. This gene encodes a member of the epidermal growth factor superfamily. The encoded preproprotein is proteolytically processed to generate the 53-amino acid epidermal growth factor peptide. This protein acts a potent mitogenic factor that plays an important role in the growth, proliferation and differentiation of numerous cell types. This protein acts by binding with high affinity to the cell surface receptor, epidermal growth factor receptor. Defects in this gene are the cause of hypomagnesemia type 4. Dysregulation of this gene has been associated with the growth and progression of certain cancers. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed. [provided by RefSeq, Jan 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
